Brief: Immuneering Announces Positive Phase 2A Data With Imm-1-104 In Combination With Chemotherapy In Pancreatic Cancer
12/09/2024 22:52
Sept 12 (Reuters) - Immuneering Corp IMRX.O :
* IMMUNEERING ANNOUNCES POSITIVE INITIAL PHASE 2A DATA
INCLUDING
COMPLETE AND PARTIAL RESPONSES WITH IMM-1-104 IN COMBINATION
WITH CHEMOTHERAPY IN FIRST-LINE PANCREATIC CANCER PATIENTS
* IMMUNEERING CORP - INITIAL RESPONSE RATE OF 40% AND
DISEASE
CONTROL RATE OF 80% OBSERVED IN PHASE 2A ARM INVESTIGATING
IMM-1-104
* IMMUNEERING CORP - IMM-1-104 WELL-TOLERATED AT 240 MG QD,
ADDITIONAL PATIENTS DOSED AT 320 MG QD
Source text for Eikon: ID:nGNXbRz2LS
Further company coverage: IMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences